Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGCD0103 in relapsed or refractory Hodgkin's lymphoma
NCT00358982Phase 2Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2006
- Primary completion
- Jan 2009
- Countries
- 2
01
Overview
A Phase 2 trial of mocetinostat in Hodgkin lymphoma (HL), sponsored by Mirati Therapeutics. Started Aug 2006; status: terminated.
02
Drugs
mocetinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00358982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358982.